KNSA logo

Kiniksa Pharmaceuticals International plc (KNSA)

$95.11

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on KNSA

Market cap

$7.47B

EPS

1.31

P/E ratio

82.2

Price to sales

7.4

Dividend yield

--

Beta

0.071389

Price on KNSA

Previous close

$94.23

Today's open

$94.23

Day's range

$93.29 - $95.70

52 week range

$37.02 - $99.31

Profile about KNSA

CEO

Sanj K. Patel

Employees

366

Headquarters

London,

Exchange

Nasdaq Global Select

Shares outstanding

78571705

Issue type

Common Stock

KNSA industries and sectors

Healthcare

Biotechnology & Life Sciences

News on KNSA

Kiniksa Pharmaceuticals to Present at Jefferies Global Healthcare Conference in London

LONDON, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Monday, November 16, 2026 at 11:00 a.m. Greenwich Mean Time (6:00 a.m. Eastern Time).

news source

GlobeNewsWire • Nov 11, 2026

news preview

Here's Why Kiniksa Pharmaceuticals International, plc (KNSA) is a Strong Momentum Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

news source

Zacks Investment Research • Nov 4, 2026

news preview

Kiniksa Pharmaceuticals: 3 Key Takeaways for Long-Term Investors

Kiniksa raised 2026 revenue guidance to over $1.045 billion. ARCALYST penetration among multiple recurrence patients reached 23%.

news source

The Motley Fool • Oct 27, 2026

news preview

What Kiniksa Pharmaceuticals International (KNSA) Said on Its Q3 Earnings Call

Kiniksa Pharmaceuticals International NASDAQ: KNSA raised its full-year 2026 revenue guidance after reporting third-quarter ARCALYST revenue growth of 58% year over year, as the company continued to expand use of the drug for recurrent pericarditis and advance its clinical pipeline.

news source

MarketBeat • Oct 27, 2026

news preview

Kiniksa Pharmaceuticals International, plc (KNSA) Q3 2026 Earnings Call Transcript

Kiniksa Pharmaceuticals International, plc (KNSA) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Oct 27, 2026

news preview

Kiniksa Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Portfolio Execution

– ARCALYST ® (rilonacept) Q3 2026 net product revenue of $286.0 million, representing ~58% year-over-year growth – – ARCALYST 2026 expected net product revenue increased to $1.045 - $1.050 billion – – KPL-387 pivotal Phase 3 data expected in 2H 2027 – – Conference call and webcast scheduled for 8:30 am ET today – LONDON, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today reported third quarter 2026 financial results and recent portfolio execution. “Kiniksa continues to build a leading IL-1α and IL-1β inhibition franchise, driven by the commercialization of ARCALYST in recurrent pericarditis.

news source

GlobeNewsWire • Oct 27, 2026

news preview

Kiniksa Pharmaceuticals International, plc (KNSA) Q3 Earnings and Revenues Surpass Estimates

Kiniksa Pharmaceuticals International, plc (KNSA) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of $0.32 per share. This compares to earnings of $0.23 per share a year ago.

news source

Zacks Investment Research • Oct 27, 2026

news preview

Kiniksa Pharmaceuticals to Report Third Quarter 2026 Financial Results on October 27, 2026

LONDON, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 27, 2026 at 8:30 a.m. Eastern Time to report its third quarter 2026 financial results and recent portfolio execution.

news source

GlobeNewsWire • Oct 22, 2026

news preview

Kiniksa Pharmaceuticals Stock Rallies 41% in Three Months: Here's Why

KNSA is gaining momentum as Arcalyst sales surge and pipeline advances strengthen prospects for continued growth.

news source

Zacks Investment Research • Sep 17, 2026

news preview

Biopharmaceutical Leader Kiniksa Poised To Hit New Buy Point After Big Revenue Beat

Biotech leader Kiniksa stock is poised to hit a fresh buy point after shares soared 25% in response to better-than-expected sales numbers.

news source

Investors Business Daily • Sep 10, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Kiniksa Pharmaceuticals International plc

Open an M1 investment account to buy and sell Kiniksa Pharmaceuticals International plc commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in KNSA on M1